Announcements Trials
Browse Landscape

Status

No longer available 1

Sponsor Class

INDUSTRY 1

Study Type

Expanded_access 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Lymphoma, Follicular 9Lymphoma, Large B-Cell, Diffuse 6Sarcoma, Synovial 5Sarcoma 4Rhabdoid Tumor 3Mesothelioma 3Lymphoma, B-Cell 3Recurrence 2Prostatic Neoplasms 2Lymphoma, Non-Hodgkin 2Lymphoma, Mantle-Cell 2Lymphoma, B-Cell, Marginal Zone 2Lymphoma 2Hematologic Neoplasms 2Neoplasms 1Multiple Myeloma 1Mesothelioma, Malignant 1Hepatic Impairment 1Desmoplastic Small Round Cell Tumor 1Chondrosarcoma 1Carcinoma, Renal Cell 1

Interventions

pembrolizumab 133Gemcitabine 101Paclitaxel 100Carboplatin 84Nivolumab 66Docetaxel 62Bevacizumab 62Cisplatin 57Pemetrexed 50Fluorouracil 49Cyclophosphamide 41Cetuximab 41trametinib 38venetoclax 37Leucovorin 37Irinotecan 37Sorafenib 35Capecitabine 35Ipilimumab 33Dexamethasone 32atezolizumab 31Erlotinib Hydrochloride 28130-nm albumin-bound paclitaxel 28Drug Therapy 27Epoetin Alfa 26Doxorubicin 25Oxaliplatin 24Albumin-Bound Paclitaxel 24Prednisone 23Rituximab 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Neoplasms × tazemetostat × Clear all
NCT04225429 2024-10-01

Tazemetostat Expanded Access Program for Adults With Epithelioid Sarcoma

Ipsen

No longer available
Sarcoma

Neoplasms, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡